Holen Sie sich die Stockscreener-App
3.49
2.05%
0.07
Handel nachbörslich:
3.49
Schlusskurs vom Vortag:
$3.42
Offen:
$3.38
24-Stunden-Volumen:
95,356
Relative Volume:
0.20
Marktkapitalisierung:
$55.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1774
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
+7.06%
1M Leistung:
+3.25%
6M Leistung:
+23.28%
1J Leistung:
-1.97%
1-Tages-Spanne:
$3.2614
$3.55
1-Wochen-Bereich:
$3.07
$3.55
52-Wochen-Spanne:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.49 | 54.37M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
PolyPid Q2 2025 Earnings Call Transcript - MarketBeat
PolyPid Releases Mid-2025 Financial Update - TipRanks
PolyPid's Q2 2025 Earnings Call: Key Contradictions on CMC Readiness, GLP-1 Program, and Partnership Dynamics - AInvest
Transcript : PolyPid Ltd., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
908 Devices Inc. shares rise 8.11% intraday after PolyPid reported positive Phase 3 SHIELD II Trial Results. - AInvest
PolyPid Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
PolyPid Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
How institutional ownership impacts PolyPid Ltd. stockDay Trade & Daily Profit Focused Screening - Newser
Will PolyPid Ltd. benefit from macro trendsIndex Update & Weekly Stock Performance Updates - Newser
Risk adjusted return profile for PolyPid Ltd. analyzedTrade Analysis Report & Verified Chart Pattern Trade Signals - Newser
PolyPid Reports Positive Phase 3 Results and Strengthens Leadership - TipRanks
Does PolyPid Ltd. qualify in momentum factor screeningMarket Performance Recap & Real-Time Volume Surge Alerts - Newser
Developing predictive dashboards with PolyPid Ltd. dataJuly 2025 Sector Moves & Verified Swing Trading Watchlists - Newser
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire
PolyPid's Surgical Innovation Shows Major Infection Prevention Success, Expands into Obesity Drug Market - Stock Titan
Pattern recognition hints at PolyPid Ltd. upsideEarnings Recap Report & Low Drawdown Investment Ideas - Newser
Detecting price anomalies in PolyPid Ltd. with AI2025 Retail Activity & Stock Market Timing Techniques - Newser
Live market analysis of PolyPid Ltd.July 2025 Price Swings & High Win Rate Trade Tips - Newser
Comparing PolyPid Ltd. in custom built stock radars2025 Trading Recap & Low Risk High Reward Ideas - Newser
Why PolyPid Ltd. stock attracts strong analyst attentionBond Market & AI Powered Market Trend Analysis - Newser
What’s the recovery path for long term holders of PolyPid Ltd. [July 2025 Trends]High Accuracy Trade Alerts - Newser
Applying sector rotation models to PolyPid Ltd.Fundamental + Technical Combined Watchlist - Newser
PolyPid Appoints New Chief Medical Officer Amid Strategic Advancements - TipRanks
PolyPid Ltd. Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer - Quiver Quantitative
PolyPid appoints Dr. Tweezer-Zaks as chief medical officer By Investing.com - Investing.com South Africa
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer - GlobeNewswire
PolyPid Strengthens Leadership: Board Director Takes CMO Role Following Breakthrough Phase 3 Results - Stock Titan
Combining machine learning predictions for PolyPid Ltd.Pre-Market Stock Movement Summary and Review - Newser
PolyPid Ltd. stock volume spike explainedDeep Stock Performance and Volatility Analysis - Newser
PolyPid (PYPD) to Release Quarterly Earnings on Wednesday - Defense World
What makes PolyPid Ltd. stock price move sharplyQuarterly Investment Outlook and Key Summary - Newser
Sector ETF performance correlation with PolyPid Ltd.Long Term Stock Growth Plan Suggestions - Newser
Custom watchlist performance reports with PolyPid Ltd.Swing Entry Risk Mitigation with Chart Analysis - Newser
Running Global Clinical Trials? PolyPid Shares Operational And Regulatory Insights - Clinical Leader
Is PolyPid Ltd. a candidate for recovery playFree Trade Ready Stock Watch for Short Term - Newser
Sector ETF performance correlation with PolyPid Ltd. [Portfolio Value Summary]Weekly Watchlist of Top Performers - Newser
Financial Survey: Assertio (NASDAQ:ASRT) versus PolyPid (NASDAQ:PYPD) - Defense World
What MACD and RSI say about PolyPid Ltd.Weekly Stock Market Strategy Summary - Newser
Can PolyPid Ltd. ride the EV waveLow Risk High Return Picks - newsyoung.net
PolyPid Ltd. (NASDAQ:PYPD) Receives $11.80 Average Target Price from Analysts - Defense World
Published on: 2025-08-08 23:39:33 - Newser
Full technical analysis of PolyPid Ltd. stockMarket Liquidity and Price Flow Analysis - Newser
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):